SCHEDULE: Paradigm BioCapital Acquires 5.8% Stake in Tyra Biosciences

Paradigm BioCapital Advisors LP, along with affiliated entities, has reported beneficial ownership of 5.8% of Tyra Biosciences, Inc. common stock as of September 10, 2026.

Summary

• Paradigm BioCapital Advisors LP, and its affiliates Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd., have collectively acquired a beneficial ownership stake in Tyra Biosciences, Inc.
• The total beneficial ownership reported is 3,473,453 shares of common stock, representing 5.8% of the class.
• This ownership level is based on 59,676,939 shares of common stock outstanding as of July 31, 2026.
• The filing is a Schedule 13G, indicating passive investment intent.
• The reporting date for this ownership is September 10, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant but not controlling stake acquisition by an investment entity. The lack of negative disclosures or forward-looking statements suggests a stable, expected event.

Positives

• Significant investment by a known investment advisor (Paradigm BioCapital) in Tyra Biosciences, Inc.
• The acquisition of a 5.8% stake suggests confidence in the company's future prospects by the reporting persons.
• The filing is a Schedule 13G, which is typically used for passive investors, implying no intent to control or influence the company's management.

Negatives

• No specific negative financial or operational information is disclosed in this filing.
• The filing does not provide details on the acquisition cost or the specific strategy behind the investment.

Risks

• As a Schedule 13G filing, it indicates passive ownership, but any shift in strategy could lead to future changes in holdings.
• The investment is subject to market risks inherent in the biotechnology sector.

Future Outlook

This filing is a Schedule 13G, which reports passive ownership and does not contain forward-looking statements or specific guidance from the company or the reporting persons regarding future performance or strategy.

Management Comments

• Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment firms in biotechnology companies are common, especially for companies like Tyra Biosciences, Inc. which operate in a sector characterized by high growth potential and significant R&D investment. This filing indicates a notable but non-controlling investment.

Comparison to Industry Standards

• The acquisition of a 5.8% stake by an investment advisor is a common occurrence in the biotechnology sector, where institutional investors often build positions in promising companies.
• Companies like Tyra Biosciences, Inc. are frequently subject to such filings as they advance their drug development pipelines.
• The passive nature of the filing (Schedule 13G) aligns with typical investment strategies in the sector, where investors aim for capital appreciation without direct operational control.

Stakeholder Impact

• Shareholders: The acquisition of a significant stake by an investment firm may be viewed positively, potentially indicating increased investor interest and confidence in the company.
• Management: The passive nature of the investment (Schedule 13G) suggests no immediate intent to influence management decisions, but significant ownership can lead to increased scrutiny.
• Potential Investors: This filing may attract further attention from other investors interested in Tyra Biosciences, Inc.

Next Steps

• The reporting persons will continue to monitor their investment in Tyra Biosciences, Inc.
• Further filings may be required if the beneficial ownership percentage changes significantly.

Key Dates

Keywords

Tyra Biosciences, Paradigm BioCapital, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Biotechnology